MYC is a global cancer driver deregulated in virtually all BL (typically, via an IG::MYC translocation) but also in roughly 30–40% of DLBCL featuring increased proliferation-associated transcription as reflected by upregulated expression of spot D (Figure 2d, see also [48] and references cited therein). This evidence concerns the gene MYC and cancer.